Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis

Respiratory Medicine

Volumn 109, Issue 7, 2015, Pages 914-922

  Nathan, Steven D ^a   Du Bois, Roland M ^b   Albera, Carlo ^c   Bradford, Williamson Z ^d   Costabel, Ulrich ^e   Kartashov, Alex ^f   Noble, Paul W ^g   Sahn, Steven A ^h   Valeyre, Dominique ⁱ   Weycker, Derek ^f   King, Talmadge E ^j  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF TURIN   (Italy)

^d InterMune Inc   (United States)

^e RUHRLANDKLINIK   (Germany)

^f POLICY ANALYSIS INC PAI   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

6 minute walk test; Dyspnea; Idiopathic pulmonary fibrosis; Lung function; Minimal clinically important difference

Indexed keywords

HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIRFENIDONE; PYRIDONE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

6 MINUTE WALK TEST; ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; DYSPNEA; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; HUMAN; IDIOPATHIC DISEASE; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXYGEN TENSION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ST. GEORGE RESPIRATORY QUESTIONNAIRE; UNIVERSITY OF CALIFORNIA SAN DIEGO SHORTNESS OF BREATH QUESTIONNAIRE; VALIDATION STUDY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FOLLOW UP; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; QUESTIONNAIRE; TIME; VERY ELDERLY; WALKING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PROGNOSIS; PYRIDONES; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WALKING;

EID: 84930960053     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2015.04.008     Document Type: Article

References (28)

1. G. Raghu, H.R. Collard, and J.J. Egan An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 2011 788 824
2. T.E. King Jr., W.Z. Bradford, and S. Castro-Bernardini A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N Engl J Med 370 2014 2083 2092
3. S.D. Nathan, R.M. du Bois, and C. Albera 6-minute walk test (6MWT) in patients with idiopathic pulmonary fibrosis (IPF): confirmation of test performance characteristics Am J Respir Crit Care Med 187 2013 A2360
4. R.M. Rudd, R.J. Prescott, and J.C. Chalmers British Thoracic Society study on cryptogenic fibrosing alveolitis: response to treatment and survival Thorax 62 2007 62 66
5. R.P. Baughman, B.K. Sparkman, and E.E. Lower Six minute walk test and health status assessment in sarcoidosis Chest 132 2007 207 213
6. M.L. Bernstein, J.A. Despars, and N.P. Singh Reanalysis of the 12-minute walk in patients with chronic obstructive pulmonary disease Chest 105 1994 163 167
7. L.P. Cahalin, M.A. Mathier, and M.J. Semigran The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure Chest 110 1996 325 332
8. M. Gomberg-Maitland, D. Huo, and R.L. Benza Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension J Heart Lung Transpl 26 2007 732 738
9. D.P. Lipkin, A.J. Scriven, and T. Crake Six minute walking test for assessing exercise capacity in chronic heart failure Br Med J 292 1986 653 655
10. A. Caminati, A. Bianchi, and R. Cassandro Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis Respir Med 103 2009 117 123
11. A. Chetta, M. Aiello, and A. Foresi Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease Sarcoidosis Vasc Diffuse Lung Dis 18 2001 170 175
12. T. Eaton, P. Young, and D. Milne Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia Am J Respir Crit Care Med 171 2005 1150 1157
13. T.S. Hallstrand, L.J. Boitano, and W.C. Johnson The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis Eur Respir J 25 2005 96 103
14. A.E. Holland, C.J. Hill, and M. Conron Small changes in six-minute walk distance are important in diffuse parenchymal lung disease Respir Med 103 2009 1430 1435
15. D.J. Lederer, S.M. Arcasoy, and J.S. Wilt Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 174 2006 659 664
16. J.J. Swigris, F.S. Wamboldt, and J. Behr The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference Thorax 65 2010 173 177
17. R.M. du Bois, D. Weycker, and C. Albera Six-minute walk test in idiopathic pulmonary fibrosis. Test validation and minimal clinically important difference Am J Respir Crit Care Med 183 2011 1231 1237
18. R.M. du Bois, C. Albera, and W.Z. Bradford 6-Minute walk test distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis Eur Respir J 43 2014 1421 1429
19. S.D. Nathan, C. Albera, and R.M. du Bois 6-Minute walk test in patients with idiopathic pulmonary fibrosis: confirmation of the minimal clinically important difference Poster presented at: European Respiratory Society September 1-5, 2012 [Vienna, Austria]
20. S.D. Nathan, O.A. Shlobin, and N. Weir Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium Chest 140 2011 221 229
21. P.W. Noble, C. Albera, and W.Z. Bradford Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 377 2011 1760 1769
22. E.G. Eakin, P.M. Resnikoff, and L.M. Prewitt Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire Chest 113 1998 619 624
23. P.W. Jones, F.H. Quirk, and C.M. Baveystock The St. George's Respiratory Questionnaire Respir Med 85 suppl B 1991 25 31
24. J. Cohen Statistical power analysis for the behavioral sciences 2nd ed. 1988 Lawrence Erlbaum Associates New Jersey
25. P.D. Allison Survival analysis using the SAS system: a practical guide 1995 SAS Institute, Inc. Cary, NC 292
26. K.W. Wyrich, N.A. Nienaber, and W.M. Tierney Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life Med Care 37 1999 469 478
27. K.W. Wyrich, W.M. Tierney, and F.D. Wolinsky Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life J Clin Epidemiol 52 1999 861 873
28. K.J. Yost, and D.T. Eton Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience Eval Health Prof 28 2005 172 191